The Peptide Alliance — The Standard in Regenerative Health

Among growth hormone-stimulating peptides, the CJC-1295 + Ipamorelin stack has become one of the most widely used combinations in peptide therapy and research. The pairing is popular because the two peptides work through complementary but distinct mechanisms, producing a more physiological and robust growth hormone release than either compound alone.

This guide explains how each peptide works, why they are stacked together, what the research shows, and how typical dosing protocols are structured.

Understanding the Growth Hormone Axis

To understand how CJC-1295 and Ipamorelin work, it helps to understand the basic framework of growth hormone regulation.

The body regulates GH release through two primary hormones from the hypothalamus:

GHRH (Growth Hormone Releasing Hormone): Stimulates the pituitary to release GH
Somatostatin: Inhibits GH release, acting as a brake on the system

GH is released in pulses — primarily during deep sleep and in response to fasting and exercise. These pulses decline significantly with age, which is associated with changes in body composition, recovery capacity, and metabolic health.

Both CJC-1295 and Ipamorelin amplify GH release, but through different pathways.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of GHRH (Growth Hormone Releasing Hormone), the 44-amino-acid peptide that signals the pituitary gland to release growth hormone.

Natural GHRH has a half-life of only a few minutes in the bloodstream. CJC-1295 was engineered to solve this problem — it contains modifications that dramatically extend its half-life.

CJC-1295 With DAC vs. Without DAC

This is one of the most commonly confused points in peptide discussions:

CJC-1295 with DAC (Drug Affinity Complex): Binds to albumin in the blood, extending its half-life to 6–8 days. This creates a sustained, steady elevation in baseline GH levels rather than a pulsatile release. Often called "CJC-1295 with DAC."
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29): Has a half-life of approximately 30 minutes, producing a more pulsatile, physiologically natural GH release. This is the form most commonly stacked with Ipamorelin.

For most protocols focused on preserving the natural pulsatile nature of GH release, CJC-1295 without DAC (Mod GRF 1-29) is preferred.

What Is Ipamorelin?

Ipamorelin is a growth hormone secretagogue (GHS) and GHRP (Growth Hormone Releasing Peptide) — specifically, it is a selective ghrelin receptor agonist (GHSR agonist).

Rather than mimicking GHRH, Ipamorelin works through a completely different pathway: it binds to ghrelin receptors in the pituitary gland, triggering GH release independently of GHRH signaling.

Why Ipamorelin Stands Out Among GHRPs

Earlier GHRPs like GHRP-2 and GHRP-6 also stimulate GH release through ghrelin receptors, but they come with side effects including:

Significant cortisol and prolactin elevation (GHRP-2)
Strong appetite stimulation and hunger (GHRP-6)

Ipamorelin is highly selective — it stimulates GH release without significantly raising cortisol, prolactin, or ACTH at standard doses. This cleaner profile makes it the preferred GHRP for most protocols.

Why Stack CJC-1295 and Ipamorelin Together?

The combination works so well because CJC-1295 and Ipamorelin act on two separate but synergistic pathways:

CJC-1295 (GHRH analogue): Amplifies the GHRH signal from the hypothalamus, increasing the magnitude of each GH pulse
Ipamorelin (GHRP): Acts on ghrelin receptors to trigger GH release and simultaneously suppresses somatostatin, removing the brake on GH secretion

The result is a significantly larger GH pulse than either peptide produces alone, while still being pulsatile and physiologically appropriate — not a continuous flat elevation in GH.

Research has shown that combining a GHRH analogue with a GHRP can produce synergistic GH release far beyond additive effects, making the stack one of the more efficient approaches to GH optimization.

Benefits of the CJC-1295 + Ipamorelin Stack

The benefits associated with optimized GH levels through this stack include:

Improved body composition: Increased lean muscle mass and reduced fat mass, particularly visceral fat
Enhanced recovery: Faster recovery from training and injury through GH's role in protein synthesis and tissue repair
Improved sleep quality: GH is primarily secreted during deep sleep; users frequently report deeper, more restorative sleep
Skin and connective tissue health: GH stimulates collagen synthesis, supporting skin elasticity and joint integrity
Metabolic improvements: Enhanced fat oxidation and insulin sensitivity
Anti-aging effects: Partial reversal of age-related GH decline

Dosing Protocols

Standard research protocols for the CJC-1295 + Ipamorelin stack:

Typical Dosing

CJC-1295 without DAC: 100–300 mcg per injection
Ipamorelin: 100–300 mcg per injection
Both are injected simultaneously, typically subcutaneously

Timing

Timing matters because GH release is governed by somatostatin cycles. Common protocols include:

Before bed: Most popular option — aligns with the natural overnight GH pulse, with the added benefit of improved sleep quality. Fast for 2–3 hours before injecting.
Upon waking (fasted): Takes advantage of the natural morning GH pulse and the elevated GH response in a fasted state.
Two or three times daily: More aggressive protocols used in clinical settings, though not typically necessary for general wellness applications.

Cycle Length

Most protocols run 3–6 months on, with a 1–2 month break. Some clinical applications use longer continuous protocols. Cycling helps maintain receptor sensitivity.

What to Expect

Timeline of commonly reported effects:

Weeks 1–2: Improved sleep quality, occasional vivid dreams, mild water retention
Weeks 3–6: Improved recovery, reduced soreness, early changes in body composition
Months 2–3: More noticeable changes in muscle tone and fat reduction, improved skin texture
Months 4–6: Maximum body composition changes, sustained energy and recovery improvements

Finding Verified CJC-1295 and Ipamorelin Sources

As with all research peptides, quality verification is critical. HPLC purity, mass spectrometry confirmation, and endotoxin testing should be confirmed via independent CoA before use.

Browse the Peptide Alliance directory for growth hormone peptides to compare verified suppliers with documented quality testing.

Summary

The CJC-1295 + Ipamorelin stack is one of the most scientifically sound approaches to GH optimization available. By combining a GHRH analogue with a selective GHRP, the stack amplifies natural GH release through two independent pathways, producing synergistic results with a favorable safety profile.

For anyone researching growth hormone peptide protocols, this stack represents a well-studied, widely-used starting point.

CJC-1295 + Ipamorelin: The Growth Hormone Peptide Stack Explained